Title : ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.

Pub. Date : 2020 May

PMID : 32250167






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival. Doxorubicin DNA damage inducible transcript 3 Homo sapiens